

Dealing with Danger in the CNS: The Response of the Immune System to Injury

Sachin P. Gadani,^{1,2,3,4} James T. Walsh,^{1,2,3,4} John R. Lukens,^{1,2,*} and Jonathan Kipnis^{1,2,3,*}

¹Center for Brain Immunology and Glia, Department of Neuroscience

²Graduate Program in Neuroscience

³Medical Scientist Training Program

School of Medicine, University of Virginia, Charlottesville, VA 22908, USA

⁴Co-first author

*Correspondence: jrl7n@virginia.edu (J.R.L.), kipnis@virginia.edu (J.K.)

<http://dx.doi.org/10.1016/j.neuron.2015.05.019>

Fighting pathogens and maintaining tissue homeostasis are prerequisites for survival. Both of these functions are upheld by the immune system, though the latter is often overlooked in the context of the CNS. The mere presence of immune cells in the CNS was long considered a hallmark of pathology, but this view has been recently challenged by studies demonstrating that immunological signaling can confer pivotal neuroprotective effects on the injured CNS. In this review, we describe the temporal sequence of immunological events that follow CNS injury. Beginning with immediate changes at the injury site, including death of neural cells and release of damage-associated molecular patterns (DAMPs), and progressing through innate and adaptive immune responses, we describe the cascade of inflammatory mediators and the implications of their post-injury effects. We conclude by proposing a revised interpretation of immune privilege in the brain, which takes beneficial neuro-immune communications into account.

Neuro-immune Communication

The immune system exists pervasively throughout the body, defending against invaders, supporting tissue healing, and maintaining homeostasis. Though clearly important in the periphery, its role in the central nervous system (CNS) is complicated by several unique mechanisms. The unperturbed CNS is separated from the periphery by the blood-brain barrier (BBB), a selectively permeable barrier that prevents immune cell infiltration and free passage of bloodborne molecules into the healthy brain (Broadwell and Sofroniew, 1993; Bush et al., 1999; Habgood et al., 2007; Muldoon et al., 2013). Furthermore, early experiments by Peter Medawar and others demonstrated that foreign tissue grafted into the CNS elicits a delayed immune response (Medawar, 1948). These observations paved the way for the concept of CNS “immune privilege,” that the brain was privileged from normal immune surveillance. Indeed, in the healthy state, no peripheral immune cells are detectable in the CNS parenchyma, although resident microglia are found throughout the brain, and the meningeal spaces are highly populated by various immune cells (Derecki et al., 2010; Kivisäkk et al., 2009; Shechter et al., 2013; Louveau et al., 2015).

The nature of neuroimmune interactions is controversial, with various factors, including the concept of immune privilege, the existence of the BBB, and the observation that excessive auto-immune CNS inflammation drives pathology in multiple sclerosis (Ousman et al., 2007; Steinman, 2014), contributing to the notion that the activity of the peripheral immune system is harmful to the CNS and does not support its function. This was the prevailing dogma for decades, but over the past few years, it has been increasingly challenged. Emerging data suggest that the peripheral immune system indeed participates in the maintenance of homeostatic brain functions, with reports showing key neuroim-

une interactions regulating adult neurogenesis, learning behavior, the ability to cope with psychological stress, and other brain functions (reviewed in Kipnis et al., 2012). Persuasive evidence indicates, moreover, that the immune system also supports the injured CNS (Raposo and Schwartz, 2014; Walsh et al., 2014b), offers protection against CNS infections (Norose et al., 2011), and plays a beneficial role in pathological states such as Alzheimer’s disease (Hickman and El Khoury, 2010), glaucoma (Schwartz and London, 2009), and several other neurological disorders (Derecki et al., 2012; Frenkel et al., 2003; Yong and Rivest, 2009).

The role of the immune system in the context of CNS injury has been particularly well studied. Injury to the CNS elicits a distinct inflammatory cascade that begins with cell death and progresses through multiple molecular and cellular phases (Figure 1). This is similar to the inflammatory cascade described in injuries to peripheral tissues, where the immune system, if well controlled, is generally thought to support healing. However, the consequences of the immune response to CNS injury remain controversial, with some groups reporting aspects of it to be beneficial (Huang et al., 1999; Kurimoto et al., 2013; Shechter et al., 2009; Walsh et al., 2015; Yin et al., 2006), while others describe it as destructive (Evans et al., 2014; Gonzalez et al., 2007; Kroner et al., 2014; Popovich et al., 1999; Yawata et al., 2008).

DAMPs, PAMPs, and Alarmins—Dialing 911 for Tissue Injury

The immune system has evolved to respond not only to pathogens but also to virtually any insult that threatens homeostasis, including trauma, cellular and metabolic dysfunction, ischemia-reperfusion injury, or environmental irritants. Inflammation occurs




Figure 1. Kinetics of the Molecular and Cellular Immune Response to CNS Injury

(A) The phases of molecular and cellular inflammation after CNS injury. DAMPs such as IL-33, HMGB1, and ATP are released immediately following CNS injury. The inflammasome is activated soon after and produces mature IL-1 β and IL-18. Neutrophils arrive hours after injury and stay for several days, while monocytes begin infiltrating within the first day and remain present. Lymphocytes begin to arrive days to weeks post-injury.

(B) Specific inflammatory molecules active at each time post-injury are listed. GDNF, glial cell line-derived neurotrophic factor; BDNF, brain-derived neurotrophic factor; ROS, reactive oxygen species.

readily after sterile insults (Chen and Nuñez, 2010) and generally entails a stereotypical cascade of recruitment of neutrophils, monocytes, and lymphocytes to the site of injury and their activation there. This recruitment of peripheral immune cells is preceded by an immediate response from local cells that sense danger and “sound the alarm” by producing chemokines and cytokines. Immune activation is a tightly controlled process, and with good reason; an inappropriate response can result in devastating damage to CNS tissue and the development of autoimmune disease, while the inability to mount a proper immune response when needed can have fatal consequences.

How do cells discern between health and injury—sounding the alarm and initiating an immune response only when necessary? A classical explanation is that the immune system discriminates between “self” and “non-self” (Janeway, 1992), using specialized T- and B-cell receptors that respond to foreign antigens and only mounting a response to anything deemed “non-self.” This explanation is clearly not satisfactory as, in the context of sterile inflammation, there would be no “non-self” antigens to trigger a response. An alternate model for how the immune system chooses whether or not to respond, coined by Matzinger as the “danger theory,” states that, rather than responding to self versus non-self, the immune system initially responds to danger or damage signals that can be either pathogen- or self-derived (Matzinger, 2001, 2002). Thus, damage-associated molecular patterns (DAMPs) can be either endogenously derived “alarmins” or exogenous “pathogen-associated molecular patterns” (PAMPs) (Bianchi, 2007). PAMPs and alarmins represent the presence of pathogen or tissue damage, respectively, and are detected by pattern recognition receptors (PRRs) to initiate and amplify an immune response (Bianchi, 2007). Many types of DAMPs are expressed in the healthy CNS and are released after injury to initiate inflammation.

DAMPs encompass an extremely diverse class of molecules, ranging from bacterial lipids or peptides to endogenous proteins, nucleic acids, and metabolites. Though diverse, all DAMPs share

the characteristic of promoting immune activation in response to damage. A well-characterized group of DAMPs consists of intracellular proteins that are expressed at a basal level within a cell and are released after cell injury. Examples of endogenous protein DAMPs are interleukin (IL)-1 α (Eigenbrod et al., 2008), IL-33 (Schmitz et al., 2005), high-mobility group protein B1 (HMGB1) (Scaffidi et al., 2002), and the S100 class of proteins (Zitvogel et al., 2010), all of which bind specific receptors and promote initiation of inflammation after injury. It is interesting that many endogenous protein DAMPs (including IL-33, HMGB1, and IL-1 α) are concentrated in the nucleus, where they presumably perform non-alarmin functions, though these are generally not fully understood.

A second class of DAMPs comprises nucleic acids and nucleotide derivatives. Among the best described of these is mitochondrial DNA (mtDNA). While eukaryotic DNA has a characteristic methylation pattern that renders it non-immunogenic, mtDNA more closely resembles prokaryotic DNA (Zhang et al., 2010) and is capable of stimulating some of the same pathways as those evolved for sensing pathogenic bacteria. mtDNA becomes more immunogenic when oxidized, a condition that occurs under severe cell stress and endows it with greater specificity for damaged cells (Ding et al., 2013). ATP and uric acid are two purine nucleotide derivatives that also have well-studied alarmin properties. ATP is a multifunctional molecule, well known for storing energy and as a signaling molecule that can mediate diverse effects. Abundant ATP in the extracellular space is also detected by the immune system as a DAMP. However, another nucleotide-derived DAMP is uric acid, a metabolite that is soluble intracellularly, but upon exposure to the extracellular environment precipitates and forms crystals of monosodium urate. Both uric acid and ATP can activate the inflammasome cascade (described in detail later) and, through it, promote the production of several inflammatory chemokines and cytokines (Kim et al., 2015; Lee et al., 2012).

DAMPs alert the immune response to tissue damage, and although sterile inflammation can promote wound healing, it can also potentiate disease. In recent years, non-communicable chronic diseases that are potentiated by dysregulated sterile inflammation have replaced infectious diseases as the preeminent threat to human health (GBD 2013 Mortality and Causes

of Death, 2015). Persisting sterile inflammation that results from aberrant tissue damage, indeed, plays pivotal roles in the pathogenesis of various prevalent human diseases, including atherosclerosis, type 2 diabetes, obesity, and some neurodegenerative diseases (Lukens et al., 2012b).

PRRs Alert the Immune System to Pathogens and Cell Damage

PRRs represent a large group of receptors with an even larger repertoire of potential ligands. There are numerous PRR families, including the Toll-like receptors (TLRs), NOD-like receptors (NLRs), AIM2-like receptors (ALRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs). Each of these categories has multiple representatives and species differences; for example, humans have 10 TLRs and 22 NLRs, whereas mice have 12 TLRs and 34 NLRs (Bryant and Monie, 2012). Many of these PRRs, in turn, have multiple ligands, often a combination of PAMPs and DAMPs. One example is the TLR4, well known for binding to lipopolysaccharide (LPS) found on the outer core of Gram-negative bacteria, which also binds to a wide array of endogenous DAMPs, such as HMGB1 (Erridge, 2010).

Despite their diversity of receptors and ligands, specific classes of PRRs tend to induce similar intracellular signaling cascades. For example, TLRs are found on intra- or extracellular membranes and typically signal through MyD88 and/or TRIF in response to protein or nucleic acid DAMPs (Erridge, 2010). NLRs are cytoplasmic PRRs and often signal through the inflammasome protein complex (Latz et al., 2013). RLRs, cytoplasmic PRRs that recognize double-stranded RNA, play an important role in host defense against viruses by recruiting the adaptor protein IPS1 and signaling through the interferon (IFN) regulatory factor (IRF) family and necrosis factor κ B (NF- κ B) transcription factors (Loo and Gale, 2011). ALRs are also found in the cytosol and initiate inflammasome activation following recognition of cytosolic double-stranded DNA (Ratsimandresy et al., 2013). A final PRR is the receptor for advanced glycation endproducts (RAGE). This receptor, found on the extracellular surface, was originally described as a receptor that recognizes glycosylated proteins and lipids, but was later found also to detect other proteins such as S100B, amyloid-beta fibrils, and the alarmin HMGB1 (Xie et al., 2013). RAGE couples with mDia1 and Src to activate a myriad of signaling pathways that affect cell survival, autophagy, cell motility, and inflammation (through NF- κ B) (reviewed in (Xie et al., 2013)).

CNS Injury

Millions of people suffer traumatic CNS injuries every year (Rutland-Brown et al., 2006). Although the results can be quite variable, depending on the location and severity of trauma, CNS injuries fail to regenerate over time and often lead to permanent disability (Ruffolo et al., 1999). Traumatic spinal cord injury (SCI), for example, results in at least some degree of paralysis on discharge in over 99% of cases (National Spinal Cord Injury Statistical Center, 2014). Coupled with this poor prognosis is a dire lack of effective therapies. The only pharmacological treatment currently approved for improvement of neurologic recovery after SCI is methylprednisone, a glucocorticoid with immunosup-

pressive properties. Though this has been the standard care for many years, evidence in support of its beneficial effects is limited (Bracken, 2012), and its use is currently under debate (Lammerse, 2013).

Why does the CNS not recover after injury? Neuroscientists have been mystified by this question for decades, and as yet, no single explanation can fully provide the answer. In general, obstacles to recovery can be divided into two categories: barriers to regeneration, either neuron intrinsic (Liu et al., 2011) or neuron extrinsic (Fawcett et al., 2012); and secondary death—the persistence, in the days and weeks after injury, of ongoing progressive neuronal degeneration beyond the primary lesion (Algattas and Huang, 2014; Yoles and Schwartz, 1998). Untreated or inadequately treated, these two major phenomena are targeted by neuroregenerative and neuroprotective agents, respectively, and represent the bulk of efforts in the quest for effective therapies for CNS injury.

Cell Death after CNS Injury

As touched upon earlier, injury to the CNS is characterized by two distinct phases of cell death. First, mechanical trauma at the time of injury causes direct damage to neurons, glia, vasculature, and meningeal cells, inducing necrotic death of neurons and glia (Grossman et al., 2001). Then, over the following days and weeks an ongoing process of secondary death leads to increased lesion size and worsened outcome, primarily owing to apoptotic cell death (Dusart and Schwab, 1994; Liu et al., 1997; Lytle and Wrathall, 2007). The kinetics and relative contribution of primary versus secondary death to total neuron loss varies between injuries and depends, in particular, on the severity of injury (Yoles and Schwartz, 1998). In the case of crush injury to the spinal cord, most of the motor neurons that suffered mechanical damage are lost in minutes to hours after the injury (Fehlings et al., 2012). Similarly, the trauma is rapidly followed by a primary wave of glial degeneration (Fehlings et al., 2012), where astrocytes undergo maximal loss within 24 hr (Lytle and Wrathall, 2007) and CC1⁺ oligodendrocytes degenerate over the first post-injury week (Casha et al., 2001). Secondary death of both neurons and glia is caused by the combined effects of noxious stimuli from free radicals generated after injury (Algattas and Huang, 2014; Carrico et al., 2009); excitotoxicity owing to the release of glutamate from neurons, microglia, and macrophages (Yawata et al., 2008); swelling of injured tissue, causing its further crushing within limited space (Bareyre et al., 1997); hypoxia and metabolic dysfunction that results from impaired blood flow (a switch from aerobic to anaerobic glycolysis among other things) (Algattas and Huang, 2014); and aspects of inflammation (Loane and Byrnes, 2010).

Inflammation begins soon after injury and remains a prominent force throughout its progression (Shechter and Schwartz, 2013). In subsequent sections, we will discuss the molecular and cellular inflammatory events that occur in the minutes, days, and weeks after CNS injury. Particular attention will be focused on the initiation of CNS inflammation and the implications of immune-cell activity for injury outcome, with the goal of outlining our current understanding of CNS inflammation and its beneficial and detrimental effects.




Figure 2. Necrotic Cell Death Causes the Release of Alarmins into the Extracellular Space

Necrotic cell death releases peptide and nucleic acid derivative alarmins that initiate inflammation. IL-33 plays an important role in bringing monocyte-derived macrophages into the CNS through upregulation of astrocytic chemokine expression. ATP promotes chemotaxis of neutrophils (through its activation of the inflammasome) and is directly chemotactic to microglial processes. ATP and uric acid also activate the inflammasome, stimulating the assembly of the cytosolic NLR, ASC, and pro-caspase 1. Pro-caspase 1 is auto-cleaved to mature caspase 1, which cleaves pro-IL-1β and pro-IL-18 to active forms and IL-33 to an inactive form. HMGB1 acts on TLR4 and RAGE receptors and directly promotes inflammatory cytokine and chemokine production. An important transcription factor downstream of both receptors is NF-κB, important in enhancing inflammation and cellular infiltration, but the RAGE receptor has several other downstream signaling pathways (not shown here). IL-1α and uric acid (gray arrows) are important inducers of immune responses in response to tissue damage in the periphery; however, their roles in response to CNS injury remained poorly defined.

vation results in production of the inflammatory cytokines IL-1β and IL-18, which exert broad proinflammatory effects, including induction of chemokine production (Lukens et al., 2012b). ATP is a potent stimulator of several chemokines, including CCL3, produced by microglia (Kataoka et al., 2009), and CCL2, produced by astrocytes (Panenka et al., 2001). ATP signaling is particularly critical for neutrophil recruitment, as transcranial delivery (through diffusion across a thinned skull) of a purine receptor antagonist can suppress neutrophil responses following traumatic brain injury (TBI) (Roth et al., 2014). Although the chemo-

tactic effect of ATP on neutrophils can be direct (Chen et al., 2006), the results in the TBI model were consistent with inflammasome inhibition (thus resulting in decreased neutrophil chemotaxis) (McDonald et al., 2010). Microglial processes are also highly sensitive to ATP, showing dramatic chemotaxis to ATP gradients (Davalos et al., 2005). Two-photon in-vivo imaging disclosed that within minutes microglia respond in an ATP-dependent manner to cortical injury (Davalos et al., 2005; Nimmerjahn et al., 2005). Interestingly, high extracellular ATP can induce further release of ATP from astrocytes, and such ATP-induced ATP release is an important mechanism for amplifying its alarmin effects in both neutrophil and microglial chemotaxis (Davalos et al., 2005; Roth et al., 2014).

HMGB1

HMGB1 is a ubiquitous nuclear protein that is expressed in virtually all cells of the CNS (Daston and Ratner, 1994; Enokido et al., 2008; Gao et al., 2011; Tenenbaum et al., 2006). HMGB1 has

Immediately after Injury: Alarmin Release and Glial Activation

As discussed earlier, injury to peripheral tissues results in cell death and the release of alarmins with subsequent induction of inflammation (Chen and Nuñez, 2010). Which alarmins, if any, initiate inflammation after CNS injury? Below we discuss three alarmins—ATP, HMGB1, and IL-33—that have been shown to act in the CNS (Figure 2).

ATP

ATP participates in many signaling events, both in physiological and in pathological contexts (reviewed in Franke et al., 2012), and its presence in the extracellular space does not always imply cell damage. However, when released abundantly and in conjunction with other DAMPs, ATP plays an important role in initiating the immune response to CNS trauma. Release of ATP generally promotes inflammation by inciting the inflammasome activity of NLRP3, a cytoplasmic NLR (Di Virgilio, 2007). This acti-

been shown to play pleiotropic roles in the CNS in both health and disease. It is important, for instance, in zebrafish brain development (Zhao et al., 2011) and continues to serve an architectural and maintenance role in the nucleus of adult cells (Lange and Vasquez, 2009). After injury, however, extracellular HMGB1 serves as a potent activator of inflammation (Chen et al., 2011; Scaffidi et al., 2002). Once released, HMGB1 can signal via both TLR4 and RAGE receptors to potentiate the migration, proliferation, and differentiation of immune cells (De-gryse et al., 2001).

In the CNS, HMGB1 strongly upregulates several chemokines in astrocytes, including neutrophil chemoattractants such as CXCL1, CXCL2, and CCL3, and T-cell chemoattractants such as CX3CL1, CCL2, CCL5, and CCL20 (Pedrazzi et al., 2007). HMGB1 has also been shown to potentiate post-traumatic CNS damage that correlates with increased infiltration of neutrophils. Inhibition of HMGB1 by antibody-mediated neutralization or by pharmacological blockers was found to lead to improved recovery from both SCI (Zhai et al., 2012) and TBI (Gu et al., 2014; Okuma et al., 2012). Furthermore, genetic ablation of the RAGE receptor was reported to improve outcome in a mouse model of SCI (Guo et al., 2014). Notably, HMGB1 has also been found to be beneficial in promoting CNS repair in non-mammalian organisms. For example, a gecko paralog of HMGB1 was shown to signal via RAGE to oligodendrocytes to coordinate myelination after CNS injury (Dong et al., 2013) and to neurons to promote neurite outgrowth (Saleh et al., 2013). HMGB1 also contributes to axonal regeneration and recovery after spinal cord transection in a zebrafish model (Fang et al., 2014). The opposing roles of HMGB1 described in different organisms may be less puzzling, however, given a recent study demonstrating that paralogs of gecko HMGB1 have other functions, unrelated to inflammation, that directly support remyelination and CNS regeneration in these animals (Dong et al., 2013).

IL-33

Like HMGB1, IL-33 is a nuclear alarmin that is widely expressed in many tissues, with the highest expression observed in the skin, lung, brain, and spinal cord (Schmitz et al., 2005). In the nucleus, IL-33 appears to participate in gene silencing through its association with heterochromatin (Carriere et al., 2007), but this notion has been contested by high-resolution imaging methodologies showing that it actually associates with euchromatin (Kakkar et al., 2012). The precise role of IL-33 in the nuclei of healthy cells remains poorly characterized. Its functions are clearer, however, after cellular injury. IL-33 is released after cellular necrosis and acts through its specific receptor (IL-33R), a heterodimer of ST2 and the IL-1-receptor-associated protein (IL-1RAP), to initiate inflammation in multiple cell types.

The IL-33R signals through MyD88, the adaptor protein also used by most TLRs and the IL-1 receptor, and similarly results in activation of NF- κ B and MAP kinase signaling. Specific expression of the IL-33R by certain immune cells links IL-33 to type 2 immune responses. These responses, typically found in asthma, allergy, and anti-parasite immunity, are associated with mast cells, type 2 innate lymphocytes (ILC2s), and type 2 helper T cells (Th2s), all of which exhibit enriched IL-33R expression.

High levels of IL-33 expression in the CNS were originally reported some 10 years ago (Schmitz et al., 2005), but its cellular

expression pattern, its function as an alarmin, and its actions on local cells there remain an active area of investigation. Early studies yielded somewhat conflicting reports on IL-33 regulation and localization in the CNS. In-vitro-cultured astrocytes express IL-33, and this expression was greatly potentiated by treatment with other DAMPs (Hudson et al., 2008; Yasuoka et al., 2011). Another group, studying IL-33 in the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis, reported IL-33 expression in healthy astrocytes and neurons, with little change after EAE induction (Jiang et al., 2012). In yet another study of the regulation of IL-33 expression in the developing CNS, IL-33 was produced in both developing astrocytes and oligodendrocyte precursor cells (OPCs) (Wicher et al., 2013). However, this group did not detect IL-33 expression in adult animals.

We recently readdressed the question of IL-33 expression in the healthy adult CNS by first measuring IL-33 mRNA in several different tissues and brain regions (Gadani et al., 2015). A strong correlation was identified between myelination and IL-33 content among brain regions, which ultimately reflected enriched expression of IL-33 in CC1⁺ oligodendrocytes. IL-33 was also generally expressed by astrocytes in gray matter but not in white matter. In contrast, IL-33 expression was not detectable in microglia, neurons, or OPCs. Flow cytometric analysis of whole brain showed that approximately 30% of all brain cells express IL-33 (Gadani et al., 2015). Furthermore, IL-33 was released by CNS tissue after injury, becoming detectable in the cerebrospinal fluid after spinal cord contusion and in the supernatant of in-vitro-damaged spinal cords. Secretion of IL-33 following tissue damage in vitro was not associated with enhanced IL-33 expression, suggesting that its release after CNS damage is probably not a result of increased IL-33 transcription but rather the release of endogenously expressed protein (Gadani et al., 2015).

IL-33 is known to influence inflammation in many peripheral disease models (Oboki et al., 2010), in sepsis (Jiang et al., 2012) and in EAE (Jiang et al., 2012; Oboki et al., 2010), but its role in the post-injury regulation of CNS repair is only now beginning to be elucidated. IL-33 can stimulate CCL2 production by mixed glia in vitro (Gadani et al., 2015; Kempuraj et al., 2013), and IL-33^{-/-} mice show significantly reduced production of several chemokines at the injury site after SCI (Gadani et al., 2015). This defect in chemokine expression was coupled with reduced recruitment of peripheral monocytes, impaired recovery, and increased lesion volume after SCI and with decreased neuronal survival after optic nerve crush (Gadani et al., 2015). Furthermore, exogenous administration of CCL2 into the site of SCI in IL-33^{-/-} mice was found to promote recovery, suggesting that delayed monocyte recruitment underlies increased pathology in these animals (Gadani et al., 2015). It is interesting that IL-33 signaling can also be potentiated to improve outcomes in wild-type (WT) mice, as intraperitoneal injection of exogenous IL-33 was found to improve locomotor recovery and reduce lesion size after SCI (Pomeshchik et al., 2015).

It should be noted that many of the alarmins and DAMPs—including IL-1 α , mtDNA, and uric acid—shown to coordinate immune responses to peripheral tissue injury have not been adequately studied in the context of in vivo injury to the CNS.

Future studies will be needed in order to delineate the involvement of these molecules in the regulation of responses to CNS injury.

Minutes to Hours after CNS Injury: Inflammasome Activation, Cytokine Production, and Neutrophil Recruitment

Cytokine Secretion and the Inflammasome

DAMPs released immediately after injury initiate a cascade of cellular and molecular immune mediators to amplify inflammation. Early molecular players in this cascade include cytokines such as tumor necrosis factor (TNF), IL-6, and IL-1 β , which are upregulated rapidly by local and infiltrating immune cells in response to DAMPs (Ransohoff and Brown, 2012). These molecules are critical amplifiers of the innate immune response to CNS injury and represent potential therapeutic targets. For example, TNF has been identified as a detrimental cytokine, expressed early after injury by red-blood-cell-engulfing macrophages (Kroner et al., 2014). Furthermore, studies blocking early TNF signaling in vivo show promise in rodent models and humans to improve outcome after CNS trauma (Esposito and Cuzzocrea, 2011). Similarly blocking IL-6 signaling promotes recovery in rodent spinal cord injury (Mukaino et al., 2010; Okada et al., 2004).

One of the most potent mechanisms by which DAMPs can provoke inflammatory signaling is through the activation of inflammasome platforms and release of cytokines such as IL-1 β . Inflammasomes are multiprotein complexes that generally consist of three main components: a cytosolic PRR, the enzyme caspase-1, and the adaptor protein apoptosis-associated, speck-like protein containing CARD (ASC) (Lukens and Kanneganti, 2014). Recognition of PAMPs and DAMPs by inflammasome-associated PRRs promotes the assembly of inflammasome components into a multiprotein complex and culminates in the secretion of active IL-1 β and IL-18. The generation of mature IL-1 β and IL-18 is a coordinated multi-step process, where the first step requires transcription and translation of pro-IL-1 β and pro-IL-18 and is often initiated by TNF-, IL-1 α -, or TLR-induced activation of NF- κ B signaling (Bauernfeind et al., 2009). The second step requires assembly of the intracellular PRR, the adaptor protein ASC, and pro-caspase-1. These proteins form the inflammasome complex, which is needed to orient pro-caspase-1 for autocleavage and activation. Once activated, caspase-1 cleaves pro-IL-1 β and pro-IL-18, providing the final step required for their secretion and inflammatory signaling (Figure 2).

Members of the NLR and ALR families, as well as the protein Pylrin, have all been shown to function as cytoplasmic PRRs that coordinate inflammasome formation and activation. To date, a number of NLRs (NLRP1, NLRP3, NLRP6, NLRP7, NLRP12, and NLRC4) and ALRs (AIM2 and IFI16) have been reported to induce inflammasome activation (Latz et al., 2013; Lukens and Kanneganti, 2014). These intracellular PRRs can orchestrate inflammasome signaling in response to a variety of diverse pathogen- or danger-associated triggers. For example, the ALRs AIM2 and IFI16 activate the inflammasome in response to the presence of cytosolic DNA (Fernandes-Alnemri et al., 2009; Hornung et al., 2009; Roberts et al., 2009), whereas

NLRC4 induces inflammasome signaling following recognition of bacterial flagellin or type III secretion system-associated bacterial proteins (Wang et al., 2011). NLRP3, on the other hand, can trigger inflammasome formation and activation in response to both pathogenic and endogenous danger signals (Strowig et al., 2012). Examples of NLRP3 inflammasome triggers that are released in response to CNS trauma include ATP, uric acid, reactive oxygen species, and necrotic cells. It is interesting that NLRP3 inflammasome-dependent cytokine production was recently reported to contribute to the pathogenesis of multiple neuroinflammatory and neurodegenerative disorders, including multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) (Halle et al., 2008; Lukens et al., 2012a; Meissner et al., 2010). Inflammasome-associated proteins are highly expressed in the CNS, and inflammasomes have been reported to assemble in glial cells and neurons (Liu et al., 2013; Tomura et al., 2012; Walsh et al., 2014a).

Recent studies suggest critical roles for inflammasomes in promoting CNS tissue damage in models of TBI and SCI (de Rivero Vaccari et al., 2012). In both cases, neutralization of the NLRP1 and NLRP3 inflammasomes with anti-ASC antibodies significantly decreased the post-injury pathology (ASC is an intracellular target, and although that study showed that anti-ASC antibodies reduce inflammasome activity and enter neurons, it is unclear conceptually how this happens) (de Rivero Vaccari et al., 2008, 2009). While those authors focused on and attributed the observed effects to neuronal inflammasomes, treatment with anti-ASC antibodies should globally disrupt inflammasome mobilization in all CNS cells and would also, in theory, affect glial inflammasomes. Therefore, it remains unclear whether the most potent inflammasome-mediated IL-1 β production after injury is exhibited by microglia, neurons, or astrocytes. Those few initial works imply harmful roles for inflammasome activation in models of CNS injury. Additional studies are needed, however, to establish how specific inflammasome-derived cytokines and downstream events, such as pyroptosis, contribute to overall disease pathogenesis.

Inflammasome activation also has implications for the alarmin IL-33. This alarmin is a member of the IL-1 cytokine family, along with IL-1 β , IL-1 α , and IL-18. Cleavage by caspase-1, in contrast to its effect on IL-1 β and IL-18, *inactivates* IL-33 (Cayrol and Girard, 2009). Certain other cleavage forms of IL-33, however, are more potent than the native form, particularly, the products of neutrophil elastase and cathepsin G cleavage (Lefrançois et al., 2012). This makes sense, given the alarmin nature of IL-33. IL-1 β is produced by effector cells and requires multiple signals to become fully active. IL-33, on the other hand, carries a rapid message from necrotic cells and, therefore, logically requires no processing to elicit its activity. Furthermore, neutrophils generally degranulate at the injury site, secreting enzymes such as elastase that can cleave native IL-33 to a more active form and reinforce the effect of its release soon after injury, before IL-33 can be neutralized by the inflammasome (Lefrançois et al., 2012).

Innate Immunity: Neutrophils

After most injuries, the first peripheral cells to arrive on the scene are neutrophils. These are granular cells that are continuously produced in the bone marrow and, after a short life in

circulation—about 5 days in humans and 12 hr in mice (Pillay et al., 2010)—are cleared by bone marrow and liver macrophages (Shi et al., 2001; Summers et al., 2010). Once mobilized to a site of irritant-induced tissue damage, neutrophils can exert potent effector functions that include the rapid release of cytokines, chemokines, lytic enzymes, and growth factors (Summers et al., 2010). As with other injuries, large numbers of neutrophils appear at the site of CNS injury as soon as 4 hr after its occurrence and remain there for 2–3 days (Carlson et al., 1998; Trivedi et al., 2006). Numerous factors can promote neutrophil recruitment, including the chemokines KC and MIP2 (CXCL1 and CXCL2, respectively). A recent study also showed that purinergic-receptor-induced signaling, probably via inflammasome activity and increased chemokine production, profoundly influences neutrophil mobilization to sites of CNS injury (Roth et al., 2014).

Neutrophils are specialists in fighting pathogens, secreting key anti-microbial products, but their impact on sterile injury is less clear. Following their extravasation, neutrophils release large amounts of effector molecules including proteases, cytokines, and free oxygen radicals to combat any invading pathogens (Amulic et al., 2012). On neuronal cells, however, these efforts have nonspecific and harmful effects. Blocking of the neutrophil-secreted enzyme elastase, indeed, improved recovery of rats after SCI (Tonai et al., 2001). Prevention of neutrophil migration into injured CNS tissue through inhibition of CXCR2 was found to ameliorate post-injury neuronal loss (Semple et al., 2010) as well as to promote tissue repair and enhance functional recovery (Gorio et al., 2007). An alternative method of preventing neutrophil influx into the injured tissue was based on knockout of C5, a neutrophil chemotactic component of the complement cascade; C5^{-/-} mice were shown to have a deficit in neutrophil infiltration into the site of cryoinjury that correlated with a decrease in lesion size (Sewell et al., 2004). A number of other studies have linked beneficial pharmacological treatment to a decrease in initial neutrophil recruitment (Naruo et al., 2003).

Despite the wealth of supporting evidence, however, it might be premature to conclude that neutrophils are universally detrimental in CNS injury. In one study the authors sought to directly address the role of neutrophils in SCI by depleting mice of neutrophils using a depleting antibody that targeted the neutrophil surface protein Ly6G/GR-1. These mice showed worse functional hindlimb recovery and delayed astrocyte reactivity, suggesting that neutrophils have a positive effect on the local glial response (Stirling et al., 2009). An important caveat acknowledged by those authors, however, was the nonspecific nature of the cell depletion. Neutrophils in the antibody-treated mice were severely reduced, but both circulating monocytes and lymphocytes were also lowered, albeit to a lesser extent (Stirling et al., 2009). Another study of neutrophil depletion after crush injury of the mouse optic nerve (this time using a more neutrophil-specific Ly6G clone) also demonstrated a beneficial role for neutrophils, and showed that improved outcome of CNS injury was associated with their production of the atypical growth factor oncomodulin (Kurimoto et al., 2013). Given the existing data, therefore, it remains unclear whether the overall effect of neutrophils is beneficial or detrimental, and isolated aspects

of their function can have dichotomous effects on outcome (Figure 3).

Hours to Days Post-CNS Injury: Infiltration of Monocytes Innate Immunity: Monocyte-Derived Macrophages

Blood monocytes can be classified into two types based on their surface molecule profiles and unique functions: Ly6C^{hi} monocytes, which express the chemokine receptor CCR2 and low levels of the chemokine receptor CX3CR1, and Ly6C^{lo} monocytes (blood-resident monocytes), which express high levels of CX3CR1. Ly6C^{hi} monocytes circulate in the blood and are recruited to sites of tissue injury in response to endothelial activation and chemokine gradients. Monocyte-derived macrophages (from now on termed just “macrophages” to distinguish them from microglia and other tissue-resident populations) are prominent cells at injury sites.

Macrophages are generally believed to carry out beneficial functions such as orchestrating wound-healing responses and coordinating the removal of debris in models of peripheral tissue injury. Infiltrating macrophages initially promote inflammation, but later, they are necessary for its proper resolution, promotion of angiogenesis, scar formation, and secretion of growth factors (reviewed in Brancato and Albina, 2011; Koh and DiPietro, 2011; Werner and Grose, 2003). As expected on the basis of these functions, ablation of macrophages delays normal peripheral wound-healing responses in rodents (Mirza et al., 2009; Ramsebner et al., 2010) and regeneration of limbs in amphibians (Godwin et al., 2013). Macrophages are also important to regeneration after peripheral nerve injury, where they are robustly recruited by Schwann cells along the injured nerve and play a vital role in clearing myelin and apoptotic debris (Brosius Lutz and Barres, 2014; Tofaris et al., 2002; Vargas et al., 2010). The role of macrophages after CNS injury, however, is more controversial, with studies showing them to be either beneficial (Batchelor et al., 1999; Gadani et al., 2015; Kotter et al., 2001; London et al., 2011; Prewitt et al., 1997; Shechter et al., 2009, 2013; Yin et al., 2006) or harmful (Evans et al., 2014; Horn et al., 2008; McPhail et al., 2004; Popovich et al., 1999), as discussed in detail in the next section.

Beneficial versus Destructive Roles of Macrophages in CNS Injury

After entering the CNS injury site, macrophages have several functions; some of them have been shown to be beneficial, and others have been shown to be detrimental (Figure 3). A well-known neurotoxic product of activated microglia and macrophages is glutamate, a primary CNS excitatory neurotransmitter, which is released in large quantities after injury and contributes to both neuronal excitotoxicity and secondary degeneration (Bullock et al., 1995; Doble, 1999; Yawata et al., 2008). Moreover, TNF—a cytokine robustly produced after injury—is a major stimulator of microglial production of glutamate and can further potentiate glutamate-induced killing of neurons (Leonoudakis et al., 2008; Olmos and Lladó, 2014). Macrophages also contribute to secondary death through the production of nitric oxide synthase (iNOS) and free radicals. Free oxygen radicals are abundantly produced at the injury site and contribute to neuronal death (Lewén et al., 2000; Roth et al., 2014). Expression of iNOS by macrophages and




Figure 3. Beneficial and Detrimental Roles for Macrophages and Neutrophils in CNS Injury

Macrophages and neutrophils have been described to promote both beneficial and detrimental outcomes following CNS injury. Whether these cells orchestrate CNS repair or exacerbate tissue damage following CNS trauma depends on the specific factors that are generated. Beneficial roles for macrophages (top left) in the CNS include their ability to clear cell debris and produce growth factors and other protective molecules, including BDNF, glial cell line-derived neurotrophic factor (GDNF), and IL-10. Detrimental roles for macrophages (top right) include production of glutamate and contact-mediated axon dieback. Both macrophages and neutrophils beneficially produce the atypical growth factor oncomodulin and clear pathogens in non-sterile injuries (left) and detrimentally produce the free radical nitric oxide (right). Neutrophils additionally secrete the enzyme elastase, which was shown to be detrimental following injury (right).

perivascular cell is upregulated within hours of injury, and subsequent production of nitrogen oxide radicals can provoke neuronal apoptosis (Satake et al., 2000). Studies by Jerry Silver and colleagues have uncovered direct contacts between macrophages and neurons both in vivo and in vitro, which appear to precede and correlate with axon retraction (Evans et al., 2014; Horn et al., 2008). The nature of this interaction and its molecular mediators or purposes is unclear. However, axon retraction in vivo is markedly reduced by treatment with clodronate liposomes, which kill engulfing phagocytes (Horn et al., 2008).

In addition to the many reports on the detrimental effects of macrophages, evidence from numerous labs suggests that macrophages also contribute to tissue protection and regeneration after CNS injury. Macrophages secrete growth-promoting molecules, including neurotrophins and oncomodulin (Dougherty et al., 2000; Hashimoto et al., 2005; Yin et al., 2006), phagocytose inhibitory myelin debris (Ma et al., 2002), and promote pathogen clearance in non-sterile injuries (Shi and Pamer, 2011). One compelling link between inflammation and axon regrowth is oncomodulin, an atypical growth factor mentioned earlier as a neutrophil product. Oncomodulin is a potent factor in promoting axonal growth and is also produced by inflammatory macrophages after CNS injury (Yin et al., 2006). Stimulation of macrophages with the TLR2 agonist zymosan increases macrophage production of oncomodulin, which promotes axon regrowth in vitro and in vivo through the activation of CaMKII-dependent

signaling (Yin et al., 2006). While its effects have been well studied in the eye, less is known about the role of oncomodulin in other CNS injury models such as SCI or TBI.

Shechter et al. (2009) addressed the overall impact of macrophages on SCI using two methods: by increasing the pool of monocytes via adoptive transfer and by depleting myeloid cells using the CD11c^{DTR} → WT bone marrow chimeric mouse (diphtheria toxin receptor [DTR] is expressed only on CD11c⁺ cells, allowing bloodborne macrophages to be targeted). In both conditions, macrophages proved beneficial; the addition of macrophages increased functional recovery, while their ablation with CD11c^{DTR} exacerbated CNS pathology (Shechter et al., 2009). A major function identified in that work and ascribed to macrophages was production of IL-10, a cytokine that both dampens and promotes resolution of inflammation (Shechter et al., 2009). This study supported previously observed beneficial aspects (mostly reported from the same lab) of boosting macrophage numbers after CNS injury (Bomstein et al., 2003; Lazarov-Spiegler et al., 1998; Rapalino et al., 1998; Schwartz, 2010; Schwartz et al., 1999; Schwartz and Yoles, 2006).

In one line of experiments spanning numerous studies over several decades, homologous macrophages were activated in vitro in co-culture with explanted tissue that typically heals well (such as skin or peripheral nerve) before they were delivered directly to the CNS injury site (Schwartz, 2010; Schwartz and Yoles, 2006). The intention was to add phagocytes

and encourage debris clearance, exploiting their activation by DAMPs from the skin (or other tissue with efficient healing properties) to instruct macrophages to become better tissue healers. This strategy proved beneficial in animal models of SCI (Schwartz, 2010) and was tested in phase I (Knoller et al., 2005) and phase II clinical trials (Jones et al., 2010; Lammertse et al., 2012), although it did not proceed to phase III trials (Lammertse et al., 2012).

Macrophage Polarization in CNS Injury: Is It Really that Simple?

Macrophages are heterogeneous immune cells that can be activated to fight pathogens and promote tissue regeneration (Epelman et al., 2014). These functions are often attributed to two macrophage phenotypes: M1 and M2. These phenotypes and their respective stimuli have been well described in vitro. M2 macrophages are induced by the cytokines IL-4 and IL-13 and characteristically express the markers arginase 1 (Arg1), CD206, and YM-1, while M1 macrophages are induced by IFN- γ and LPS and express iNOS, TNF, and CCL5 as markers (Gordon, 2003; Sica and Mantovani, 2012). As described earlier, discrete beneficial and detrimental functions after CNS injury have been defined for macrophages (Figure 3). M1/M2 skewing is a convenient paradigm for explaining these divergent macrophage effects, with M1 products being harmful and M2 products being beneficial, and numerous studies have been focused on macrophage skewing and the proportions of M1 versus M2 macrophages in the injured CNS (Girard et al., 2013; Kigerl et al., 2009; Kumar et al., 2013; Stirling et al., 2014; Turtzo et al., 2014; Wang et al., 2013). However, it is becoming increasingly evident that, although these paradigms clearly exist under controlled in vitro settings, they are too simplistic to describe macrophage phenotypes in vivo (Martinez and Gordon, 2014; Murray et al., 2014). This is apparent after CNS injury, where M1 and M2 markers do not appear in discrete groups but are often expressed simultaneously by inflammatory macrophages. For example, at early time points after injury (1–3 days), both the M1 marker *Nos2* (the gene that encodes iNOS) and the M2 marker *Arg1* (the gene encoding Arg1) are upregulated at the injury site (Kigerl et al., 2009). In another study by Hsieh et al. (2013), Arg1-positive cells were isolated from mice and analyzed by microarray analysis on day 3 post-TBI. They found, notably, that Arg1-positive cells, although assumed to be M2, do not express many other M2 markers and actually express multiple M1 markers (including *nos2*, consistent with the aforementioned findings of Kigerl et al.) (Hsieh et al., 2013). These findings are not altogether surprising, as it is known that macrophage polarization is not stringently defined in vivo (Martinez and Gordon, 2014). Macrophages can exhibit simultaneous expression of M1 and M2 markers and may be able, given appropriate stimuli, to switch phenotypes (Pettersen et al., 2011; Sica and Mantovani, 2012; Vogel et al., 2013).

Under normal physiological conditions, macrophage subsets in the body are heterogeneous (Ginhoux et al., 2010), and individual characteristics are imparted by tissue-specific signals (Butovsky et al., 2014; Okabe and Medzhitov, 2014). It is likely that similar heterogeneity in the macrophage population also develops after CNS injuries and that, under those conditions, the unique infiltrating macrophage phenotype is influenced by

a myriad of extracellular and inflammatory signals that ensue as a result of CNS tissue damage.

In summary, M1/M2 classifications, as they exist under in vitro conditions, do not appear to apply neatly to macrophages after CNS injury, and recent findings highlight the diversity of macrophage phenotypes that can arise from different stimulations (Xue et al., 2014). Therefore, it seems that, rather than trying to fit CNS-infiltrating macrophages into categories that are largely based on responses to isolated stimuli in vitro, efforts would be better spent in attempting to understand the unique subset(s) existing at the CNS injury site. These subsets can probably not be defined simply as “inflammatory” (M1) and “anti-inflammatory” (M2) but rather by unique, nuanced sets of functions and markers that are dependent on complex temporal, spatial, and signaling factors.

The ultimate role of macrophages in any sterile injury, and particularly in CNS injury, is an area of active investigation. Macrophages have been reported to perform both beneficial and detrimental functions in response to CNS trauma, but the degree of impairment caused by their depletion suggests that their overall role is protective (Gadani et al., 2015; Shechter et al., 2009). Improved characterization of the discrete macrophage phenotypes that arise in response to CNS injury will help to uncover the specific molecular pathways that promote beneficial macrophage responses during trauma and can be expected to aid in the development of novel macrophage-based therapies for the treatment of CNS injury.

Days to Weeks Post-CNS Injury: Recruitment of Adaptive Immune Cells

As with macrophages and neutrophils, the beneficial or detrimental nature of the adaptive immune system in CNS injury is a hazy picture that is slowly becoming better defined. Partly based on early dogma in the field of CNS injury, adaptive immune responses to the injury were assumed to be largely detrimental by default (Hickey et al., 1991; Popovich et al., 1996). Strikingly, however, secondary degeneration is more extensive in rodents that lack both T and B cells than in their WT counterparts (Moalem et al., 1999; Serpe et al., 1999; Yoles et al., 2001), suggesting a previously unknown neuroprotective role for adaptive immune cells in CNS injury. In immunodeficient (severe combined immunodeficiency [SCID] or nude) mice, reconstitution of the immune compartment with T cells was found to improve recovery from CNS injury (Kipnis et al., 2002; Serpe et al., 2003), further suggesting that T cells have a role to play in neuroprotection. It is interesting that T cells specific to brain-restricted antigens were found to be particularly potent in promoting neuroprotection (Moalem et al., 1999), and it seemed that their migration to the injured CNS and their accumulation there were most probably governed by their CNS-antigen specificity (Archambault et al., 2005; Ling et al., 2006). Transfer of autoreactive T cells directed against CNS antigens, indeed, substantially reduced secondary degeneration after nerve injury in rats, and this neuroprotection could be conferred either by active immunization (with spinal cord homogenates or purified myelin proteins and adjuvant) or by passive immunization (via the transfer of pre-activated CNS-specific T cells) (Byram et al., 2004; Hauben et al., 2000; Moalem et al., 1999). However, antigen specificity is not

an absolute requirement for T-cell-mediated neuroprotection, as our recent studies have shown that T cells can endow appreciable neuroprotection after CNS injury, even in the absence of antigen recognition (Walsh et al., 2015).

In the adaptive immune system, pattern recognition has been largely overlooked, despite the fact that it plays an important part in the function of lymphocytes not only by affecting cellular migration and activation but also through modulation of their activity (Iwasaki and Medzhitov, 2010; Pasare and Medzhitov, 2004). Studies have identified PRRs on CD4⁺ T cells and pointed to TLR signaling as an important player in CD4⁺ T-cell-mediated neuroprotection through its activity on regulatory T cells (Pasare and Medzhitov, 2003). One of the major mechanisms underlying PRR-induced activation of immune cells is induction of MyD88-mediated signaling. We recently observed that production of the neuroprotective cytokine IL-4 by CD4⁺ T cells in response to CNS injury is not dependent on classical T cell receptor/MHC II engagement but is critically dependent on MyD88-mediated signaling (Walsh et al., 2015). These findings point to pivotal roles for PRR-triggered activation of MyD88 signaling in the generation of neuroprotective T-cell responses, although the specific PRR ligands that mediate this effect still remain to be elucidated. IL-4 production by injury-induced T cells was shown to promote CNS recovery downstream of this activation by acting on neurons directly, not via IL-4 signaling in macrophages (Walsh et al., 2015).

Conclusion

How the immune system responds to CNS injury remains a matter of debate, and there is still no general consensus as to whether it is mainly deleterious or beneficial. The notion that peripheral immunity causes only damage to the CNS is still prevalent and is supported by the early relative success of the immunosuppressive drug methylprednisone in the treatment of CNS injury and the recognition that inflammation underlies the pathology of the autoimmune disease multiple sclerosis (Steinman et al., 2002). However, as described in this review, multiple lines of evidence from various models of CNS trauma now clearly demonstrate that immune cells can also have beneficial functions in the CNS. Moreover, emerging data suggest that there is extensive crosstalk between the immune system and glial cells, even in the absence of overt CNS immunopathology. The concept of immune privilege was derived from early studies demonstrating that rejection of engrafted tissue is delayed in the brain and should not be interpreted to preclude beneficial neuroimmune interactions, either in the healthy CNS or after injury. Inflammatory cells clearly have both beneficial and detrimental functions after CNS injury, but it appears that the overall effect of immune-cell subtypes on injury, as assessed by depletion or knockout studies, is generally beneficial.

This review surveys the progress of research carried out over the past 2 decades on the immune response to CNS injury, starting with the seminal discoveries in connection with DAMPs and the initiation of inflammation and progressing through subsequent cell infiltration events. With regard to the specific events that occur in CNS injury, we note that the response of the immune system to brain injury does not differ substantially from its response to injury of any peripheral tissue.

Countries charge their military with two vital assignments: to destroy hostile groups invading their borders and to aid their citizens when the need arises to cope, for example, with natural disasters. We view the immune system as functioning in much the same way; it defends the organism against dangerous invading pathogens while also helping to protect it from the devastating effects of sterile injuries. Deeper understanding of DAMPs in the CNS will shed light on the pathologies associated with its injury as well as on a host of neurodegenerative syndromes associated with sterile inflammation, such as Alzheimer's disease (Rubio-Perez and Morillas-Ruiz, 2012), ALS (Frakes et al., 2014), autism spectrum disorder (Patterson, 2011), and epilepsy (Marchi et al., 2014). Further understanding of the initiation of inflammation will enable us to design more effective therapies for timely, beneficial modulation of the immune response.

AUTHOR CONTRIBUTIONS

S.P.G. wrote the sections of the manuscript related to innate immune response, designed the manuscript, and created the figures. J.T.W. wrote the sections of the manuscript related to adaptive immune response and participated in manuscript design. J.R.L. wrote sections of the manuscript related to inflammasomes, participated in the design, and proofread the entire manuscript. J.K. designed the manuscript, participated in writing and proofreading, and oversaw the entire process of manuscript preparation.

ACKNOWLEDGMENTS

This work was primarily supported by a grant from the National Institute of Neurological Disorders and Stroke (NS061973 award to J.K.).

REFERENCES

- Algattas, H., and Huang, J.H. (2014). Traumatic Brain Injury pathophysiology and treatments: early, intermediate, and late phases post-injury. *Int. J. Mol. Sci.* **15**, 309–341.
- Amulic, B., Cazalet, C., Hayes, G.L., Metzler, K.D., and Zychlinsky, A. (2012). Neutrophil function: from mechanisms to disease. *Annu. Rev. Immunol.* **30**, 459–489.
- Archambault, A.S., Sim, J., Gimenez, M.A., and Russell, J.H. (2005). Defining antigen-dependent stages of T cell migration from the blood to the central nervous system parenchyma. *Eur. J. Immunol.* **35**, 1076–1085.
- Bareyre, F., Wahl, F., McIntosh, T.K., and Stutzmann, J.M. (1997). Time course of cerebral edema after traumatic brain injury in rats: effects of riluzole and mannitol. *J. Neurotrauma* **14**, 839–849.
- Batchelor, P.E., Liberatore, G.T., Wong, J.Y., Porritt, M.J., Frerichs, F., Donnan, G.A., and Howells, D.W. (1999). Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. *J. Neurosci.* **19**, 1708–1716.
- Bauernfeind, F.G., Horvath, G., Stutz, A., Alnemri, E.S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Monks, B.G., Fitzgerald, K.A., et al. (2009). Cutting edge: NF- κ B activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. *J. Immunol.* **183**, 787–791.
- Bianchi, M.E. (2007). DAMPs, PAMPs and alarmins: all we need to know about danger. *J. Leukoc. Biol.* **81**, 1–5.
- Bomstein, Y., Marder, J.B., Vitner, K., Smirnov, I., Lisaey, G., Butovsky, O., Fulga, V., and Yoles, E. (2003). Features of skin-coincubated macrophages that promote recovery from spinal cord injury. *J. Neuroimmunol.* **142**, 10–16.
- Bracken, M.B. (2012). Steroids for acute spinal cord injury. *Cochrane Database Syst. Rev.* **1**, CD001046.

- Brancato, S.K., and Albina, J.E. (2011). Wound macrophages as key regulators of repair: origin, phenotype, and function. *Am. J. Pathol.* *178*, 19–25.
- Broadwell, R.D., and Sofroniew, M.V. (1993). Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. *Exp. Neurol.* *120*, 245–263.
- Brosius Lutz, A., and Barres, B.A. (2014). Contrasting the glial response to axon injury in the central and peripheral nervous systems. *Dev. Cell* *28*, 7–17.
- Bryant, C.E., and Monie, T.P. (2012). Mice, men and the relatives: cross-species studies underpin innate immunity. *Open Biol.* *2*, 120015.
- Bullock, R., Zauner, A., Myseros, J.S., Marmarou, A., Woodward, J.J., and Young, H.F. (1995). Evidence for prolonged release of excitatory amino acids in severe human head trauma. Relationship to clinical events. *Ann. N Y Acad. Sci.* *765*, 290–297, discussion 298.
- Bush, T.G., Puvanachandra, N., Horner, C.H., Polito, A., Ostenfeld, T., Svendsen, C.N., Mucke, L., Johnson, M.H., and Sofroniew, M.V. (1999). Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. *Neuron* *23*, 297–308.
- Butovsky, O., Jedrychowski, M.P., Moore, C.S., Cialic, R., Lanser, A.J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P.M., Doykan, C.E., et al. (2014). Identification of a unique TGF- β -dependent molecular and functional signature in microglia. *Nat. Neurosci.* *17*, 131–143.
- Byram, S.C., Carson, M.J., DeBoy, C.A., Serpe, C.J., Sanders, V.M., and Jones, K.J. (2004). CD4-positive T cell-mediated neuroprotection requires dual compartment antigen presentation. *J. Neurosci.* *24*, 4333–4339.
- Carlson, S.L., Parrish, M.E., Springer, J.E., Doty, K., and Dossett, L. (1998). Acute inflammatory response in spinal cord following impact injury. *Exp. Neurol.* *151*, 77–88.
- Carrico, K.M., Vaishnav, R., and Hall, E.D. (2009). Temporal and spatial dynamics of peroxynitrite-induced oxidative damage after spinal cord contusion injury. *J. Neurotrauma* *26*, 1369–1378.
- Carriere, V., Roussel, L., Ortega, N., Lacorre, D.A., Americh, L., Aguilar, L., Bouche, G., and Girard, J.P. (2007). IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. *Proc. Natl. Acad. Sci. USA* *104*, 282–287.
- Casha, S., Yu, W.R., and Fehlings, M.G. (2001). Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. *Neuroscience* *103*, 203–218.
- Cayrol, C., and Girard, J.P. (2009). The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. *Proc. Natl. Acad. Sci. USA* *106*, 9021–9026.
- Chen, G.Y., and Nuñez, G. (2010). Sterile inflammation: sensing and reacting to damage. *Nat. Rev. Immunol.* *10*, 826–837.
- Chen, Y., Corriden, R., Inoue, Y., Yip, L., Hashiguchi, N., Zinkernagel, A., Nizet, V., Insel, P.A., and Junger, W.G. (2006). ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. *Science* *314*, 1792–1795.
- Chen, K.B., Uchida, K., Nakajima, H., Yayama, T., Hirai, T., Rodriguez Guerrero, A., Kobayashi, S., Ma, W.Y., Liu, S.Y., Zhu, P., and Baba, H. (2011). High-mobility group box-1 and its receptors contribute to proinflammatory response in the acute phase of spinal cord injury in rats. *Spine* *36*, 2122–2129.
- Daston, M.M., and Ratner, N. (1994). Amphoterin (P30, HMG-1) and RIP are early markers of oligodendrocytes in the developing rat spinal cord. *J. Neurocytol.* *23*, 323–332.
- Davalos, D., Grutzendler, J., Yang, G., Kim, J.V., Zuo, Y., Jung, S., Littman, D.R., Dustin, M.L., and Gan, W.B. (2005). ATP mediates rapid microglial response to local brain injury in vivo. *Nat. Neurosci.* *8*, 752–758.
- de Rivero Vaccari, J.P., Lotocki, G., Marcillo, A.E., Dietrich, W.D., and Keane, R.W. (2008). A molecular platform in neurons regulates inflammation after spinal cord injury. *J. Neurosci.* *28*, 3404–3414.
- de Rivero Vaccari, J.P., Lotocki, G., Alonso, O.F., Bramlett, H.M., Dietrich, W.D., and Keane, R.W. (2009). Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. *J. Cereb. Blood Flow Metab.* *29*, 1251–1261.
- de Rivero Vaccari, J.P., Bastien, D., Yurcisin, G., Pineau, I., Dietrich, W.D., De Koninck, Y., Keane, R.W., and Lacroix, S. (2012). P2X4 receptors influence inflammasome activation after spinal cord injury. *J. Neurosci.* *32*, 3058–3066.
- Degryse, B., Bonaldi, T., Scaffidi, P., Müller, S., Resnati, M., Sanvito, F., Arriaggi, G., and Bianchi, M.E. (2001). The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. *J. Cell Biol.* *152*, 1197–1206.
- Derecki, N.C., Cardani, A.N., Yang, C.H., Quinnes, K.M., Crihfield, A., Lynch, K.R., and Kipnis, J. (2010). Regulation of learning and memory by meningeal immunity: a key role for IL-4. *J. Exp. Med.* *207*, 1067–1080.
- Derecki, N.C., Cronk, J.C., Lu, Z., Xu, E., Abbott, S.B., Guyenet, P.G., and Kipnis, J. (2012). Wild-type microglia arrest pathology in a mouse model of Rett syndrome. *Nature* *484*, 105–109.
- Di Virgilio, F. (2007). Liaisons dangereuses: P2X(7) and the inflammasome. *Trends Pharmacol. Sci.* *28*, 465–472.
- Ding, Z., Liu, S., Wang, X., Khaidakov, M., Dai, Y., and Mehta, J.L. (2013). Oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis. *Sci. Rep.* *3*, 1077.
- Doble, A. (1999). The role of excitotoxicity in neurodegenerative disease: implications for therapy. *Pharmacol. Ther.* *81*, 163–221.
- Dong, Y., Gu, Y., Huan, Y., Wang, Y., Liu, Y., Liu, M., Ding, F., Gu, X., and Wang, Y. (2013). HMGB1 protein does not mediate the inflammatory response in spontaneous spinal cord regeneration: a hint for CNS regeneration. *J. Biol. Chem.* *288*, 18204–18218.
- Dougherty, K.D., Dreyfus, C.F., and Black, I.B. (2000). Brain-derived neurotrophic factor in astrocytes, oligodendrocytes, and microglia/macrophages after spinal cord injury. *Neurobiol. Dis.* *7*, 574–585.
- Dusart, I., and Schwab, M.E. (1994). Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. *Eur. J. Neurosci.* *6*, 712–724.
- Eigenbrod, T., Park, J.H., Harder, J., Iwakura, Y., and Nuñez, G. (2008). Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. *J. Immunol.* *181*, 8194–8198.
- Enokido, Y., Yoshitake, A., Ito, H., and Okazawa, H. (2008). Age-dependent change of HMGB1 and DNA double-strand break accumulation in mouse brain. *Biochem. Biophys. Res. Commun.* *376*, 128–133.
- Epelman, S., Lavine, K.J., and Randolph, G.J. (2014). Origin and functions of tissue macrophages. *Immunity* *41*, 21–35.
- Erridge, C. (2010). Endogenous ligands of TLR2 and TLR4: agonists or assistants? *J. Leukoc. Biol.* *87*, 989–999.
- Esposito, E., and Cuzzocrea, S. (2011). Anti-TNF therapy in the injured spinal cord. *Trends Pharmacol. Sci.* *32*, 107–115.
- Evans, T.A., Barkauskas, D.S., Myers, J.T., Hare, E.G., You, J.Q., Ransohoff, R.M., Huang, A.Y., and Silver, J. (2014). High-resolution intravital imaging reveals that blood-derived macrophages but not resident microglia facilitate secondary axonal dieback in traumatic spinal cord injury. *Exp. Neurol.* *254*, 109–120.
- Fang, P., Pan, H.C., Lin, S.L., Zhang, W.Q., Rauvala, H., Schachner, M., and Shen, Y.Q. (2014). HMGB1 contributes to regeneration after spinal cord injury in adult zebrafish. *Mol. Neurobiol.* *49*, 472–483.
- Fawcett, J.W., Schwab, M.E., Montani, L., Brazda, N., and Müller, H.W. (2012). Defeating inhibition of regeneration by scar and myelin components. *Handb. Clin. Neurol.* *109*, 503–522.
- Fehlings, M.G., Wilson, J.R., Frankowski, R.F., Toups, E.G., Aarabi, B., Harrop, J.S., Shaffrey, C.I., Harkema, S.J., Guest, J.D., Tator, C.H., et al. (2012). Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. *J. Neurosurg. Spine* *17* (Suppl 1), 151–156.
- Fernandes-Alnemri, T., Yu, J.W., Datta, P., Wu, J., and Alnemri, E.S. (2009). AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. *Nature* *458*, 509–513.

- Frakes, A.E., Ferraiuolo, L., Haidet-Phillips, A.M., Schmelzer, L., Braun, L., Miranda, C.J., Ladner, K.J., Bevan, A.K., Foust, K.D., Godbout, J.P., et al. (2014). Microglia induce motor neuron death via the classical NF- κ B pathway in amyotrophic lateral sclerosis. *Neuron* 81, 1009–1023.
- Franke, H., Verkhratsky, A., Burnstock, G., and Illes, P. (2012). Pathophysiology of astroglial purinergic signalling. *Purinergic Signal.* 8, 629–657.
- Frenkel, D., Huang, Z., Maron, R., Koldzic, D.N., Hancock, W.W., Moskowitz, M.A., and Weiner, H.L. (2003). Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. *J. Immunol.* 171, 6549–6555.
- Gadani, S.P., Walsh, J.T., Smirnov, I., Zheng, J., and Kipnis, J. (2015). The gliaderived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. *Neuron* 85, 703–709.
- Gao, H.M., Zhou, H., Zhang, F., Wilson, B.C., Kam, W., and Hong, J.S. (2011). HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. *J. Neurosci.* 31, 1081–1092.
- GBD 2013 Mortality and Causes of Death Collaborators (2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 385, 117–171.
- Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M.F., Conway, S.J., Ng, L.G., Stanley, E.R., et al. (2010). Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* 330, 841–845.
- Girard, S., Brough, D., Lopez-Castejon, G., Giles, J., Rothwell, N.J., and Allan, S.M. (2013). Microglia and macrophages differentially modulate cell death after brain injury caused by oxygen-glucose deprivation in organotypic brain slices. *Glia* 67, 813–824.
- Godwin, J.W., Pinto, A.R., and Rosenthal, N.A. (2013). Macrophages are required for adult salamander limb regeneration. *Proc. Natl. Acad. Sci. USA* 110, 9415–9420.
- Gonzalez, R., Hickey, M.J., Espinosa, J.M., Nistor, G., Lane, T.E., and Keirstead, H.S. (2007). Therapeutic neutralization of CXCL10 decreases secondary degeneration and functional deficit after spinal cord injury in mice. *Regen. Med.* 2, 771–783.
- Gordon, S. (2003). Alternative activation of macrophages. *Nat. Rev. Immunol.* 3, 23–35.
- Gorio, A., Madaschi, L., Zadra, G., Marfia, G., Cavalieri, B., Bertini, R., and Di Giulio, A.M. (2007). Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. *J. Pharmacol. Exp. Ther.* 322, 973–981.
- Grossman, S.D., Rosenberg, L.J., and Wrathall, J.R. (2001). Temporal-spatial pattern of acute neuronal and glial loss after spinal cord contusion. *Exp. Neurol.* 168, 273–282.
- Gu, X.J., Xu, J., Ma, B.Y., Chen, G., Gu, P.Y., Wei, D., and Hu, W.X. (2014). Effect of glycyrrhizin on traumatic brain injury in rats and its mechanism. *Chin. J. Traumatol.* 17, 1–7.
- Guo, J.D., Li, L., Shi, Y.M., Wang, H.D., Yuan, Y.L., Shi, X.X., and Hou, S.X. (2014). Genetic ablation of receptor for advanced glycation end products promotes functional recovery in mouse model of spinal cord injury. *Mol. Cell. Biochem.* 390, 215–223.
- Habgood, M.D., Bye, N., Dziegielewska, K.M., Ek, C.J., Lane, M.A., Potter, A., Morganti-Kossmann, C., and Saunders, N.R. (2007). Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. *Eur. J. Neurosci.* 25, 231–238.
- Halle, A., Hornung, V., Petzold, G.C., Stewart, C.R., Monks, B.G., Reinheckel, T., Fitzgerald, K.A., Latz, E., Moore, K.J., and Golenbock, D.T. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid- β . *Nat. Immunol.* 9, 857–865.
- Hashimoto, M., Nitta, A., Fukumitsu, H., Nomoto, H., Shen, L., and Furukawa, S. (2005). Inflammation-induced GDNF improves locomotor function after spinal cord injury. *Neuroreport* 16, 99–102.
- Hauben, E., Butovsky, O., Nevo, U., Yoles, E., Moalem, G., Agranov, E., Mor, F., Leibowitz-Amit, R., Pevsner, E., Akselrod, S., et al. (2000). Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. *J. Neurosci.* 20, 6421–6430.
- Hickey, W.F., Hsu, B.L., and Kimura, H. (1991). T-lymphocyte entry into the central nervous system. *J. Neurosci. Res.* 28, 254–260.
- Hickman, S.E., and El Khoury, J. (2010). Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. *CNS Neurol. Disord. Drug Targets* 9, 168–173.
- Horn, K.P., Busch, S.A., Hawthorne, A.L., van Rooijen, N., and Silver, J. (2008). Another barrier to regeneration in the CNS: activated macrophages induce extensive retraction of dystrophic axons through direct physical interactions. *J. Neurosci.* 28, 9330–9341.
- Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D.R., Latz, E., and Fitzgerald, K.A. (2009). AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. *Nature* 458, 514–518.
- Hsieh, C.L., Kim, C.C., Ryba, B.E., Niemi, E.C., Bando, J.K., Locksley, R.M., Liu, J., Nakamura, M.C., and Seaman, W.E. (2013). Traumatic brain injury induces macrophage subsets in the brain. *Eur. J. Immunol.* 43, 2010–2022.
- Huang, D.W., McKerracher, L., Braun, P.E., and David, S. (1999). A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord. *Neuron* 24, 639–647.
- Hudson, C.A., Christophi, G.P., Gruber, R.C., Wilmore, J.R., Lawrence, D.A., and Massa, P.T. (2008). Induction of IL-33 expression and activity in central nervous system glia. *J. Leukoc. Biol.* 84, 631–643.
- Iwasaki, A., and Medzhitov, R. (2010). Regulation of adaptive immunity by the innate immune system. *Science* 327, 291–295.
- Janeway, C.A., Jr. (1992). The immune system evolved to discriminate infectious nonself from noninfectious self. *Immunol. Today* 13, 11–16.
- Jiang, H.R., Milovanović, M., Allan, D., Niedbala, W., Besnard, A.G., Fukada, S.Y., Alves-Filho, J.C., Togbe, D., Goodyear, C.S., Linington, C., et al. (2012). IL-33 attenuates EAE by suppressing IL-17 and IFN- γ production and inducing alternatively activated macrophages. *Eur. J. Immunol.* 42, 1804–1814.
- Jones, L.A., Lammertse, D.P., Charlifue, S.B., Kirshblum, S.C., Apple, D.F., Ragnarsson, K.T., Poonian, D., Betz, R.R., Knoller, N., Heary, R.F., et al. (2010). A phase 2 autologous cellular therapy trial in patients with acute, complete spinal cord injury: pragmatics, recruitment, and demographics. *Spinal Cord* 48, 798–807.
- Kakkar, R., Hei, H., Dobner, S., and Lee, R.T. (2012). Interleukin 33 as a mechanically responsive cytokine secreted by living cells. *J. Biol. Chem.* 287, 6941–6948.
- Kataoka, A., Tozaki-Saitoh, H., Koga, Y., Tsuda, M., and Inoue, K. (2009). Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT. *J. Neurochem.* 108, 115–125.
- Kempuraj, D., Khan, M.M., Thangavel, R., Xiong, Z., Yang, E., and Zaheer, A. (2013). Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. *J. Neuroimmune Pharmacol.* 8, 643–650.
- Kigerl, K.A., Gensel, J.C., Ankeny, D.P., Alexander, J.K., Donnelly, D.J., and Popovich, P.G. (2009). Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. *J. Neurosci.* 29, 13435–13444.
- Kim, S.M., Lee, S.H., Kim, Y.G., Kim, S.Y., Seo, J.W., Choi, Y.W., Kim, D.J., Jeong, K.H., Lee, T.W., Ihm, C.G., et al. (2015). Hyperuricemia-induced NLRP3 activation of macrophage contributes to the progression of diabetic nephropathy. *Am. J. Physiol. Renal Physiol.* 308, F993–F1003.
- Kipnis, J., Mizrahi, T., Hauben, E., Shaked, I., Shevach, E., and Schwartz, M. (2002). Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. *Proc. Natl. Acad. Sci. USA* 99, 15620–15625.

- Kipnis, J., Gadani, S., and Derecki, N.C. (2012). Pro-cognitive properties of T cells. *Nat. Rev. Immunol.* *12*, 663–669.
- Kivisäkk, P., Imitola, J., Rasmussen, S., Elyaman, W., Zhu, B., Ransohoff, R.M., and Khoury, S.J. (2009). Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. *Ann. Neurol.* *65*, 457–469.
- Knoller, N., Auerbach, G., Fulga, V., Zelig, G., Attias, J., Bakimer, R., Marder, J.B., Yoles, E., Belkin, M., Schwartz, M., and Hadani, M. (2005). Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. *J. Neurosurg. Spine* *3*, 173–181.
- Koh, T.J., and DiPietro, L.A. (2011). Inflammation and wound healing: the role of the macrophage. *Expert Rev. Mol. Med.* *13*, e23.
- Kotter, M.R., Setzu, A., Sim, F.J., Van Rooijen, N., and Franklin, R.J. (2001). Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. *Glia* *35*, 204–212.
- Kroner, A., Greenhalgh, A.D., Zarruk, J.G., Passos Dos Santos, R., Gaestel, M., and David, S. (2014). TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. *Neuron* *83*, 1098–1116.
- Kumar, A., Stoica, B.A., Sabirzhanov, B., Burns, M.P., Faden, A.I., and Loane, D.J. (2013). Traumatic brain injury in aged animals increases lesion size and chronically alters microglial/macrophage classical and alternative activation states. *Neurobiol. Aging* *34*, 1397–1411.
- Kurimoto, T., Yin, Y., Habboub, G., Gilbert, H.Y., Li, Y., Nakao, S., Hafezi-Moghadam, A., and Benowitz, L.I. (2013). Neutrophils express oncomodulin and promote optic nerve regeneration. *J. Neurosci.* *33*, 14816–14824.
- Lammertse, D.P. (2013). Clinical trials in spinal cord injury: lessons learned on the path to translation. The 2011 International Spinal Cord Society Sir Ludwig Guttmann Lecture. *Spinal Cord* *51*, 2–9.
- Lammertse, D.P., Jones, L.A., Charlifue, S.B., Kirshblum, S.C., Apple, D.F., Ragnarsson, K.T., Falci, S.P., Heary, R.F., Choudhri, T.F., Jenkins, A.L., et al. (2012). Autologous incubated macrophage therapy in acute, complete spinal cord injury: results of the phase 2 randomized controlled multicenter trial. *Spinal Cord* *50*, 661–671.
- Lange, S.S., and Vasquez, K.M. (2009). HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. *Mol. Carcinog.* *48*, 571–580.
- Latz, E., Xiao, T.S., and Stutz, A. (2013). Activation and regulation of the inflammasomes. *Nat. Rev. Immunol.* *13*, 397–411.
- Lazarov-Spiegler, O., Solomon, A.S., and Schwartz, M. (1998). Peripheral nerve-stimulated macrophages simulate a peripheral nerve-like regenerative response in rat transected optic nerve. *Glia* *24*, 329–337.
- Lee, G.S., Subramanian, N., Kim, A.I., Aksentijevich, I., Goldbach-Mansky, R., Sacks, D.B., Germain, R.N., Kastner, D.L., and Chae, J.J. (2012). The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca²⁺ and cAMP. *Nature* *492*, 123–127.
- Lefrançois, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard, J.P., and Cayrol, C. (2012). IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. *Proc. Natl. Acad. Sci. USA* *109*, 1673–1678.
- Leonoudakis, D., Zhao, P., and Beattie, E.C. (2008). Rapid tumor necrosis factor alpha-induced exocytosis of glutamate receptor 2-lacking AMPA receptors to extrasynaptic plasma membrane potentiates excitotoxicity. *J. Neurosci.* *28*, 2119–2130.
- Lewén, A., Matz, P., and Chan, P.H. (2000). Free radical pathways in CNS injury. *J. Neurotrauma* *17*, 871–890.
- Ling, C., Sandor, M., Suresh, M., and Fabry, Z. (2006). Traumatic injury and the presence of antigen differentially contribute to T-cell recruitment in the CNS. *J. Neurosci.* *26*, 731–741.
- Liu, X.Z., Xu, X.M., Hu, R., Du, C., Zhang, S.X., McDonald, J.W., Dong, H.X., Wu, Y.J., Fan, G.S., Jacquin, M.F., et al. (1997). Neuronal and glial apoptosis after traumatic spinal cord injury. *J. Neurosci.* *17*, 5395–5406.
- Liu, K., Tedeschi, A., Park, K.K., and He, Z. (2011). Neuronal intrinsic mechanisms of axon regeneration. *Annu. Rev. Neurosci.* *34*, 131–152.
- Liu, H.D., Li, W., Chen, Z.R., Hu, Y.C., Zhang, D.D., Shen, W., Zhou, M.L., Zhu, L., and Hang, C.H. (2013). Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model. *Neurochem. Res.* *38*, 2072–2083.
- Loane, D.J., and Byrnes, K.R. (2010). Role of microglia in neurotrauma. *Neurotherapeutics* *7*, 366–377.
- London, A., Itskovich, E., Benhar, I., Kalchenko, V., Mack, M., Jung, S., and Schwartz, M. (2011). Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. *J. Exp. Med.* *208*, 23–39.
- Loo, Y.M., and Gale, M., Jr. (2011). Immune signaling by RIG-I-like receptors. *Immunity* *34*, 680–692.
- Louveau, A., Smirnov, I., Keyes, T.J., Eccles, J.D., Rouhani, S.J., Peske, J.D., Derecki, N.C., Castle, D., Mandell, J.W., Lee, K.S., et al. (2015). Structural and functional features of central nervous system lymphatic vessels. *Nature*. June 1, 2015. <http://dx.doi.org/10.1038/nature14432>.
- Lukens, J.R., and Kanneganti, T.D. (2014). Beyond canonical inflammasomes: emerging pathways in IL-1-mediated autoinflammatory disease. *Semin. Immunopathol.* *36*, 595–609.
- Lukens, J.R., Barr, M.J., Chaplin, D.D., Chi, H., and Kanneganti, T.D. (2012a). Inflammasome-derived IL-1 β regulates the production of GM-CSF by CD4(+) T cells and $\gamma\delta$ T cells. *J. Immunol.* *188*, 3107–3115.
- Lukens, J.R., Gross, J.M., and Kanneganti, T.D. (2012b). IL-1 family cytokines trigger sterile inflammatory disease. *Front. Immunol.* *3*, 315.
- Lytle, J.M., and Wrathall, J.R. (2007). Glial cell loss, proliferation and replacement in the contused murine spinal cord. *Eur. J. Neurosci.* *25*, 1711–1724.
- Ma, M., Wei, T., Boring, L., Charo, I.F., Ransohoff, R.M., and Jakeman, L.B. (2002). Monocyte recruitment and myelin removal are delayed following spinal cord injury in mice with CCR2 chemokine receptor deletion. *J. Neurosci. Res.* *68*, 691–702.
- Marchi, N., Granata, T., and Janigro, D. (2014). Inflammatory pathways of seizure disorders. *Trends Neurosci.* *37*, 55–65.
- Martinez, F.O., and Gordon, S. (2014). The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep.* *6*, 13.
- Matzinger, P. (2001). Essay 1: the Danger model in its historical context. *Scand. J. Immunol.* *54*, 4–9.
- Matzinger, P. (2002). The danger model: a renewed sense of self. *Science* *296*, 301–305.
- McDonald, B., Pittman, K., Menezes, G.B., Hirota, S.A., Slaba, I., Waterhouse, C.C., Beck, P.L., Muruve, D.A., and Kubes, P. (2010). Intravascular danger signals guide neutrophils to sites of sterile inflammation. *Science* *330*, 362–366.
- McPhail, L.T., Stirling, D.P., Tetzlaff, W., Kwiecien, J.M., and Ramer, M.S. (2004). The contribution of activated phagocytes and myelin degeneration to axonal retraction/dieback following spinal cord injury. *Eur. J. Neurosci.* *20*, 1984–1994.
- Medawar, P.B. (1948). Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. *Br. J. Exp. Pathol.* *29*, 58–69.
- Meissner, F., Molawi, K., and Zychlinsky, A. (2010). Mutant superoxide dismutase 1-induced IL-1 β accelerates ALS pathogenesis. *Proc. Natl. Acad. Sci. USA* *107*, 13046–13050.
- Mirza, R., DiPietro, L.A., and Koh, T.J. (2009). Selective and specific macrophage ablation is detrimental to wound healing in mice. *Am. J. Pathol.* *175*, 2454–2462.
- Moalem, G., Leibowitz-Amit, R., Yoles, E., Mor, F., Cohen, I.R., and Schwartz, M. (1999). Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. *Nat. Med.* *5*, 49–55.
- Mukaino, M., Nakamura, M., Yamada, O., Okada, S., Morikawa, S., Renault-Mihara, F., Iwanami, A., Ikegami, T., Ohsugi, Y., Tsuji, O., et al. (2010).

- Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing microglia-dominant inflammation. *Exp. Neurol.* 224, 403–414.
- Muldoon, L.L., Alvarez, J.I., Begley, D.J., Boado, R.J., Del Zoppo, G.J., Doolittle, N.D., Engelhardt, B., Hallenbeck, J.M., Lonser, R.R., Ohlfest, J.R., et al. (2013). Immunologic privilege in the central nervous system and the blood-brain barrier. *J. Cereb. Blood Flow Metab.* 33, 13–21.
- Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdts, S., Gordon, S., Hamilton, J.A., Ivashkiv, L.B., Lawrence, T., et al. (2014). Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 41, 14–20.
- Naruo, S., Okajima, K., Taoka, Y., Uchiba, M., Nakamura, T., Okabe, H., and Takagi, K. (2003). Prostaglandin E1 reduces compression trauma-induced spinal cord injury in rats mainly by inhibiting neutrophil activation. *J. Neurotrauma* 20, 221–228.
- National Spinal Cord Injury Statistical Center (2014). Facts and figures at a glance. *J. Spinal Cord Med.* 37, 243–244.
- Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science* 308, 1314–1318.
- Norose, K., Kikumura, A., Luster, A.D., Hunter, C.A., and Harris, T.H. (2011). CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis. *Invest. Ophthalmol. Vis. Sci.* 52, 389–398.
- Oboki, K., Ohno, T., Kajiwara, N., Arae, K., Morita, H., Ishii, A., Nambu, A., Abe, T., Kiyonari, H., Matsumoto, K., et al. (2010). IL-33 is a crucial amplifier of innate rather than acquired immunity. *Proc. Natl. Acad. Sci. USA* 107, 18581–18586.
- Okabe, Y., and Medzhitov, R. (2014). Tissue-specific signals control reversible program of localization and functional polarization of macrophages. *Cell* 157, 832–844.
- Okada, S., Nakamura, M., Mikami, Y., Shimazaki, T., Mihara, M., Ohsugi, Y., Iwamoto, Y., Yoshizaki, K., Kishimoto, T., Toyama, Y., and Okano, H. (2004). Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. *J. Neurosci. Res.* 76, 265–276.
- Okuma, Y., Liu, K., Wake, H., Zhang, J., Maruo, T., Date, I., Yoshino, T., Ohtsuka, A., Otani, N., Tomura, S., et al. (2012). Anti-high mobility group box-1 antibody therapy for traumatic brain injury. *Ann. Neurol.* 72, 373–384.
- Olmos, G., and Lladó, J. (2014). Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. *Mediators Inflamm.* 2014, 861231.
- Ousman, S.S., Tomooka, B.H., van Noort, J.M., Wawrousek, E.F., O'Connor, K.C., Hafner, D.A., Sobel, R.A., Robinson, W.H., and Steinman, L. (2007). Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. *Nature* 448, 474–479.
- Panenko, W., Jijon, H., Herx, L.M., Armstrong, J.N., Feighan, D., Wei, T., Yong, V.W., Ransohoff, R.M., and MacVicar, B.A. (2001). P2X7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase. *J. Neurosci.* 21, 7135–7142.
- Pasare, C., and Medzhitov, R. (2003). Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. *Science* 299, 1033–1036.
- Pasare, C., and Medzhitov, R. (2004). Toll-dependent control mechanisms of CD4 T cell activation. *Immunity* 21, 733–741.
- Patterson, P.H. (2011). Maternal infection and immune involvement in autism. *Trends Mol. Med.* 17, 389–394.
- Pedrazzi, M., Patrone, M., Passalacqua, M., Ranzato, E., Colamassaro, D., Sparatore, B., Pontremoli, S., and Melloni, E. (2007). Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. *J. Immunol.* 179, 8525–8532.
- Petersen, J.S., Fuentes-Duculan, J., Suárez-Fariñas, M., Pierson, K.C., Pitts-Kiefer, A., Fan, L., Belkin, D.A., Wang, C.Q., Bhuvanendran, S., Johnson-Huang, L.M., et al. (2011). Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. *J. Invest. Dermatol.* 131, 1322–1330.
- Pillay, J., den Braber, I., Vrisekoop, N., Kwast, L.M., de Boer, R.J., Borghans, J.A., Tesselaar, K., and Koenderman, L. (2010). In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. *Blood* 116, 625–627.
- Pomeshchik, Y., Kidin, I., Korhonen, P., Savchenko, E., Jaronen, M., Lehtonen, S., Wojciechowski, S., Kanninen, K., Koistinaho, J., and Malm, T. (2015). Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. *Brain Behav. Immun.* 44, 68–81.
- Popovich, P.G., Stokes, B.T., and Whitacre, C.C. (1996). Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system. *J. Neurosci. Res.* 45, 349–363.
- Popovich, P.G., Guan, Z., Wei, P., Huitinga, I., van Rooijen, N., and Stokes, B.T. (1999). Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. *Exp. Neurol.* 158, 351–365.
- Prewitt, C.M., Niesman, I.R., Kane, C.J., and Houlé, J.D. (1997). Activated macrophage/microglial cells can promote the regeneration of sensory axons into the injured spinal cord. *Exp. Neurol.* 148, 433–443.
- Ramsebner, R., Ludwig, M., Parzefall, T., Lucas, T., Baumgartner, W.D., Bodamer, O., Cengiz, F.B., Schoefer, C., Tekin, M., and Frei, K. (2010). A FGF3 mutation associated with differential inner ear malformation, microtia, and microdontia. *Laryngoscope* 120, 359–364.
- Ransohoff, R.M., and Brown, M.A. (2012). Innate immunity in the central nervous system. *J. Clin. Invest.* 122, 1164–1171.
- Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Velan, G.J., Yoles, E., Fridakis, M., Solomon, A., Gepstein, R., Katz, A., Belkin, M., et al. (1998). Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. *Nat. Med.* 4, 814–821.
- Raposo, C., and Schwartz, M. (2014). Glial scar and immune cell involvement in tissue remodeling and repair following acute CNS injuries. *Glia* 62, 1895–1904.
- Ratsimandresy, R.A., Dorfleutner, A., and Stehlik, C. (2013). An update on PYRIN domain-containing pattern recognition receptors: from immunity to pathology. *Front. Immunol.* 4, 440.
- Roberts, T.L., Idris, A., Dunn, J.A., Kelly, G.M., Burnton, C.M., Hodgson, S., Hardy, L.L., Garceau, V., Sweet, M.J., Ross, I.L., et al. (2009). HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. *Science* 323, 1057–1060.
- Roth, T.L., Nayak, D., Atanasijevic, T., Koretsky, A.P., Latour, L.L., and McGavern, D.B. (2014). Transcranial amelioration of inflammation and cell death after brain injury. *Nature* 505, 223–228.
- Rubio-Perez, J.M., and Morillas-Ruiz, J.M. (2012). A review: inflammatory process in Alzheimer's disease, role of cytokines. *ScientificWorldJournal* 2012, 756357.
- Ruffolo, C.F., Friedland, J.F., Dawson, D.R., Colantonio, A., and Lindsay, P.H. (1999). Mild traumatic brain injury from motor vehicle accidents: factors associated with return to work. *Arch. Phys. Med. Rehabil.* 80, 392–398.
- Rutland-Brown, W., Langlois, J.A., Thomas, K.E., and Xi, Y.L. (2006). Incidence of traumatic brain injury in the United States, 2003. *J. Head Trauma Rehabil.* 21, 544–548.
- Saleh, A., Smith, D.R., Tessler, L., Mateo, A.R., Martens, C., Schartner, E., Van der Ploeg, R., Toth, C., Zochodne, D.W., and Fernyhough, P. (2013). Receptor for advanced glycation end-products (RAGE) activates divergent signaling pathways to augment neurite outgrowth of adult sensory neurons. *Exp. Neurol.* 249, 149–159.
- Satake, K., Matsuyama, Y., Kamiya, M., Kawakami, H., Iwata, H., Adachi, K., and Kiuchi, K. (2000). Nitric oxide via macrophage iNOS induces apoptosis following traumatic spinal cord injury. *Brain Res. Mol. Brain Res.* 85, 114–122.
- Scaffidi, P., Misteli, T., and Bianchi, M.E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature* 418, 191–195.
- Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., et al. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity* 23, 479–490.

- Schwartz, M. (2010). "Tissue-repairing" blood-derived macrophages are essential for healing of the injured spinal cord: from skin-activated macrophages to infiltrating blood-derived cells? *Brain Behav. Immun.* *24*, 1054–1057.
- Schwartz, M., and Yoles, E. (2006). Immune-based therapy for spinal cord repair: autologous macrophages and beyond. *J. Neurotrauma* *23*, 360–370.
- Schwartz, M., and London, A. (2009). Immune maintenance in glaucoma: boosting the body's own neuroprotective potential. *J. Ocul. Biol. Dis. Infor.* *2*, 73–77.
- Schwartz, M., Lazarov-Spiegler, O., Rapalino, O., Agranov, I., Velan, G., and Hadani, M. (1999). Potential repair of rat spinal cord injuries using stimulated homologous macrophages. *Neurosurgery* *44*, 1041–1046.
- Semple, B.D., Bye, N., Ziebell, J.M., and Morganti-Kossmann, M.C. (2010). Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury. *Neurobiol. Dis.* *40*, 394–403.
- Serpe, C.J., Kohm, A.P., Huppenbauer, C.B., Sanders, V.M., and Jones, K.J. (1999). Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. *J. Neurosci.* *19*, RC7.
- Serpe, C.J., Coers, S., Sanders, V.M., and Jones, K.J. (2003). CD4+ T, but not CD8+ or B, lymphocytes mediate facial motoneuron survival after facial nerve transection. *Brain Behav. Immun.* *17*, 393–402.
- Sewell, D.L., Nacewicz, B., Liu, F., Macvilay, S., Erdei, A., Lambris, J.D., Sandor, M., and Fabry, Z. (2004). Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. *J. Neuroimmunol.* *155*, 55–63.
- Shechter, R., and Schwartz, M. (2013). CNS sterile injury: just another wound healing? *Trends Mol. Med.* *19*, 135–143.
- Shechter, R., London, A., Varol, C., Raposo, C., Cusimano, M., Yovel, G., Rolls, A., Mack, M., Pluchino, S., Martino, G., et al. (2009). Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. *PLoS Med.* *6*, e1000113.
- Shechter, R., Miller, O., Yovel, G., Rosenzweig, N., London, A., Ruckh, J., Kim, K.W., Klein, E., Kalchenko, V., Bendel, P., et al. (2013). Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. *Immunity* *38*, 555–569.
- Shi, C., and Pamer, E.G. (2011). Monocyte recruitment during infection and inflammation. *Nat. Rev. Immunol.* *11*, 762–774.
- Shi, J., Gilbert, G.E., Kokubo, Y., and Ohashi, T. (2001). Role of the liver in regulating numbers of circulating neutrophils. *Blood* *98*, 1226–1230.
- Sica, A., and Mantovani, A. (2012). Macrophage plasticity and polarization: in vivo veritas. *J. Clin. Invest.* *122*, 787–795.
- Steinman, L. (2014). Immunology of relapse and remission in multiple sclerosis. *Annu. Rev. Immunol.* *32*, 257–281.
- Steinman, L., Martin, R., Bernard, C., Conlon, P., and Oksenberg, J.R. (2002). Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. *Annu. Rev. Neurosci.* *25*, 491–505.
- Stirling, D.P., Liu, S., Kubes, P., and Yong, V.W. (2009). Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome. *J. Neurosci.* *29*, 753–764.
- Stirling, D.P., Cummins, K., Mishra, M., Teo, W., Yong, V.W., and Stys, P. (2014). Toll-like receptor 2-mediated alternative activation of microglia is protective after spinal cord injury. *Brain* *137*, 707–723.
- Strowig, T., Henao-Mejia, J., Elinav, E., and Flavell, R. (2012). Inflammasomes in health and disease. *Nature* *481*, 278–286.
- Summers, C., Rankin, S.M., Condliffe, A.M., Singh, N., Peters, A.M., and Chilvers, E.R. (2010). Neutrophil kinetics in health and disease. *Trends Immunol.* *31*, 318–324.
- Tenenbaum, T., Essmann, F., Adam, R., Seibt, A., Jänicke, R.U., Novotny, G.E., Galla, H.J., and Schrotten, H. (2006). Cell death, caspase activation, and HMGB1 release of porcine choroid plexus epithelial cells during *Streptococcus suis* infection in vitro. *Brain Res.* *1100*, 1–12.
- Tofaris, G.K., Patterson, P.H., Jessen, K.R., and Mirsky, R. (2002). Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. *J. Neurosci.* *22*, 6696–6703.
- Tomura, S., de Rivero Vaccari, J.P., Keane, R.W., Bramlett, H.M., and Dietrich, W.D. (2012). Effects of therapeutic hypothermia on inflammasome signaling after traumatic brain injury. *J. Cereb. Blood Flow Metab.* *32*, 1939–1947.
- Tonai, T., Shiba, K., Taketani, Y., Ohmoto, Y., Murata, K., Muraguchi, M., Oh-saki, H., Takeda, E., and Nishisho, T. (2001). A neutrophil elastase inhibitor (ONO-5046) reduces neurologic damage after spinal cord injury in rats. *J. Neurochem.* *78*, 1064–1072.
- Trivedi, A., Olivas, A.D., and Noble-Haeusslein, L.J. (2006). Inflammation and spinal cord injury: infiltrating leukocytes as determinants of injury and repair processes. *Clin. Neurosci. Res.* *6*, 283–292.
- Turtzo, L.C., Lescher, J., Janes, L., Dean, D.D., Budde, M.D., and Frank, J.A. (2014). Macrophagic and microglial responses after focal traumatic brain injury in the female rat. *J. Neuroinflammation* *11*, 82.
- Vargas, M.E., Watanabe, J., Singh, S.J., Robinson, W.H., and Barres, B.A. (2010). Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury. *Proc. Natl. Acad. Sci. USA* *107*, 11993–11998.
- Vogel, D.Y., Vereyken, E.J., Glim, J.E., Heijnen, P.D., Moeton, M., van der Valk, P., Amor, S., Teunissen, C.E., van Horsen, J., and Dijkstra, C.D. (2013). Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. *J. Neuroinflammation* *10*, 35.
- Walsh, J.G., Muruve, D.A., and Power, C. (2014a). Inflammasomes in the CNS. *Nat. Rev. Neurosci.* *15*, 84–97.
- Walsh, J.T., Watson, N., and Kipnis, J. (2014b). T cells in the central nervous system: messengers of destruction or purveyors of protection? *Immunology* *141*, 340–344.
- Walsh, J.T., Hendrix, S., Boato, F., Smirnov, I., Zheng, J., Lukens, J.R., Gadani, S., Hechler, D., Götz, G., Rosenberger, K., et al. (2015). MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. *J. Clin. Invest.* *125*, 699–714.
- Wang, H., Shen, J., Xiong, N., Zhao, H., and Chen, Y. (2011). Protein kinase B is involved in Nogo-66 inhibiting neurite outgrowth in PC12 cells. *Neuroreport* *22*, 733–738.
- Wang, G., Zhang, J., Hu, X., Zhang, L., Mao, L., Jiang, X., Liou, A.K., Leak, R.K., Gao, Y., and Chen, J. (2013). Microglia/macrophage polarization dynamics in white matter after traumatic brain injury. *J. Cereb. Blood Flow Metab.* *33*, 1864–1874.
- Werner, S., and Grose, R. (2003). Regulation of wound healing by growth factors and cytokines. *Physiol. Rev.* *83*, 835–870.
- Wicher, G., Husic, E., Nilsson, G., and Forsberg-Nilsson, K. (2013). Developmental expression of IL-33 in the mouse brain. *Neurosci. Lett.* *555*, 171–176.
- Xie, J., Méndez, J.D., Méndez-Valenzuela, V., and Aguilar-Hernández, M.M. (2013). Cellular signalling of the receptor for advanced glycation end products (RAGE). *Cell. Signal.* *25*, 2185–2197.
- Xue, J., Schmidt, S.V., Sander, J., Draffehn, A., Krebs, W., Quester, I., De Nardo, D., Gohel, T.D., Emde, M., Schmidleithner, L., et al. (2014). Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. *Immunity* *40*, 274–288.
- Yasuoka, S., Kawanokuchi, J., Parajuli, B., Jin, S., Doi, Y., Noda, M., Sonobe, Y., Takeuchi, H., Mizuno, T., and Suzumura, A. (2011). Production and functions of IL-33 in the central nervous system. *Brain Res.* *1385*, 8–17.
- Yawata, I., Takeuchi, H., Doi, Y., Liang, J., Mizuno, T., and Suzumura, A. (2008). Macrophage-induced neurotoxicity is mediated by glutamate and attenuated by glutaminase inhibitors and gap junction inhibitors. *Life Sci.* *82*, 1111–1116.
- Yin, Y., Henzl, M.T., Lorber, B., Nakazawa, T., Thomas, T.T., Jiang, F., Langer, R., and Benowitz, L.I. (2006). Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. *Nat. Neurosci.* *9*, 843–852.

- Yoles, E., and Schwartz, M. (1998). Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. *Exp. Neurol.* *153*, 1–7.
- Yoles, E., Hauben, E., Palgi, O., Agranov, E., Gothilf, A., Cohen, A., Kuchroo, V., Cohen, I.R., Weiner, H., and Schwartz, M. (2001). Protective autoimmunity is a physiological response to CNS trauma. *J. Neurosci.* *21*, 3740–3748.
- Yong, V.W., and Rivest, S. (2009). Taking advantage of the systemic immune system to cure brain diseases. *Neuron* *64*, 55–60.
- Zhai, C.L., Zhang, M.Q., Zhang, Y., Xu, H.X., Wang, J.M., An, G.P., Wang, Y.Y., and Li, L. (2012). Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. *Acta Pharmacol. Sin.* *33*, 1477–1487.
- Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., and Hauser, C.J. (2010). Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature* *464*, 104–107.
- Zhao, X., Kuja-Panula, J., Rouhiainen, A., Chen, Y.C., Panula, P., and Rauvala, H. (2011). High mobility group box-1 (HMGB1; amphoterin) is required for zebrafish brain development. *J. Biol. Chem.* *286*, 23200–23213.
- Zitvogel, L., Kepp, O., and Kroemer, G. (2010). Decoding cell death signals in inflammation and immunity. *Cell* *140*, 798–804.